Contact Us

PW Case Review Form
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

   * Please describe your case:

What injury have you suffered?

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Cafergot Gets Warning

Nov 14, 2002 | MedWatch

FDA and Novartis strengthened the labeling, including a new BOXED WARNING
and updates to the CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, and CLINICAL
PHARMACOLOGY sections of the prescribing information for Cafergot.

Serious and/or life-threatening peripheral ischemia has been associated with
the coadministration of Cafergot with potent CYP 3A4 inhibitors including
protease inhibitors and macrolide antibiotics. Because CYP 3A4 inhibition
elevates the serum levels of Cafergot, the risk for vasospasm leading to
cerebral ischemia and/or ischemia of the extremities is increased. Because
of the increased risk of serious vasospastic adverse events, concomitant use
of these medications is contraindicated.


Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo